These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8828602)

  • 1. Gene therapy for phenylketonuria.
    Eisensmith RC; Woo SL
    Eur J Pediatr; 1996 Jul; 155 Suppl 1():S16-9. PubMed ID: 8828602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy for phenylketonuria.
    Eisensmith RC; Woo SL
    Acta Paediatr Suppl; 1994 Dec; 407():124-9. PubMed ID: 7766948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer.
    Fang B; Eisensmith RC; Li XH; Finegold MJ; Shedlovsky A; Dove W; Woo SL
    Gene Ther; 1994 Jul; 1(4):247-54. PubMed ID: 7584088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.
    Ding Z; Georgiev P; Thöny B
    Gene Ther; 2006 Apr; 13(7):587-93. PubMed ID: 16319947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.
    Harding CO; Gillingham MB; Hamman K; Clark H; Goebel-Daghighi E; Bird A; Koeberl DD
    Gene Ther; 2006 Mar; 13(5):457-62. PubMed ID: 16319949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice.
    Mochizuki S; Mizukami H; Ogura T; Kure S; Ichinohe A; Kojima K; Matsubara Y; Kobayahi E; Okada T; Hoshika A; Ozawa K; Kume A
    Gene Ther; 2004 Jul; 11(13):1081-6. PubMed ID: 15057263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer.
    Oh HJ; Park ES; Kang S; Jo I; Jung SC
    Pediatr Res; 2004 Aug; 56(2):278-84. PubMed ID: 15181195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice.
    Liu TJ; Kay MA; Darlington GJ; Woo SL
    Somat Cell Mol Genet; 1992 Jan; 18(1):89-96. PubMed ID: 1312261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer.
    Nagasaki Y; Matsubara Y; Takano H; Fujii K; Senoo M; Akanuma J; Takahashi K; Kure S; Hara M; Kanegae Y; Saito I; Narisawa K
    Pediatr Res; 1999 Apr; 45(4 Pt 1):465-73. PubMed ID: 10203136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).
    Hamman KJ; Winn SR; Harding CO
    Mol Genet Metab; 2011 Nov; 104(3):235-40. PubMed ID: 21917493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria.
    Rebuffat A; Harding CO; Ding Z; Thöny B
    Hum Gene Ther; 2010 Apr; 21(4):463-77. PubMed ID: 19916803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of epidermal keratinocytes and dermal fibroblasts as potential target cells for somatic gene therapy of phenylketonuria.
    Christensen R; Güttler F; Jensen TG
    Mol Genet Metab; 2002 Aug; 76(4):313-8. PubMed ID: 12208136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic gene therapy for phenylketonuria and other hepatic deficiencies.
    Eisensmith RC; Woo SL
    J Inherit Metab Dis; 1996; 19(4):412-23. PubMed ID: 8884565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of metabolic and neurological symptoms of phenylketonuric mice treated with a PAH containing helper-dependent adenoviral vector.
    Cerreto M; Mehdawy B; Ombrone D; Nisticò R; Ruoppolo M; Usiello A; Daniele A; Pastore L; Salvatore F
    Curr Gene Ther; 2012 Feb; 12(1):48-56. PubMed ID: 22348550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel Pah-exon1 deleted murine model of phenylalanine hydroxylase (PAH) deficiency.
    Richards DY; Winn SR; Dudley S; Fedorov L; Rimann N; Thöny B; Harding CO
    Mol Genet Metab; 2020 Nov; 131(3):306-315. PubMed ID: 33051130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model.
    Kaiser RA; Weber ND; Trigueros-Motos L; Allen KL; Martinez M; Cao W; VanLith CJ; Hillin LG; Douar A; González-Aseguinolaza G; Aldabe R; Lillegard JB
    J Inherit Metab Dis; 2021 Nov; 44(6):1369-1381. PubMed ID: 33896013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State-of-the-art 2003 on PKU gene therapy.
    Ding Z; Harding CO; Thöny B
    Mol Genet Metab; 2004 Jan; 81(1):3-8. PubMed ID: 14728985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy.
    Chen L; Thung SN; Woo SL
    Mol Ther; 2007 Jun; 15(6):1079-85. PubMed ID: 17406346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retroviral-mediated gene transfer of human phenylalanine hydroxylase into NIH 3T3 and hepatoma cells.
    Ledley FD; Grenett HE; McGinnis-Shelnutt M; Woo SL
    Proc Natl Acad Sci U S A; 1986 Jan; 83(2):409-13. PubMed ID: 3455778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.
    Grisch-Chan HM; Schwank G; Harding CO; Thöny B
    Hum Gene Ther; 2019 Oct; 30(10):1274-1283. PubMed ID: 31364419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.